This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Here are five key examples of current research and innovation driving the field forward between 2024 and early 2025: Third-Generation Antiseizure Medications Show Promise Recent clinical data shared in Epilepsia spotlighted Xcopri (cenobamate), developed by SK LifeScience.
Visium Spatial GeneExpression Solution. To address challenges associated with loss of spatial context, 10x Genomics has developed the Visium Spatial GeneExpression solution, which enables answering biological questions in the context of tissue using an unbiased geneexpression approach.
In this episode, Ayesha discusses a new tool that uses CRISPR to modulate geneexpression without editing DNA sequences. Dubbed “CRISPRoff,” the technology targets the epigenome to silence genes involved in diseases, with applications in cancer, AML and other conditions with a heritable component.
More recently, MSN reported on a Cell Genomics study where CRISPR reactivated dormant genes in patient-derived cells, restoring normal geneexpression and improving metabolic function an innovation that could address PWS at its genetic roots.
A subgroup analysis revealed even greater improvement in patients with high interferon-1 (IFN-1) geneexpression, a known indicator of disease severity, with a -2.78 The cenerimod 4 mg group showed a significant improvement of -4.04 in mSLEDAI-2K compared to placebo. reduction compared to placebo.
These modifications regulate geneexpression without changing the sequence or structure of DNA. Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the LifeSciences. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed.
Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks LifeScience Podcast Ep. Secondly, other funded research is exploring differential geneexpression regulated by DNA methylation.
It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of geneexpression. Olumiant is a Janus kinase (JAK) inhibitor that was first discovered by Incyte and then licensed to Eli Lilly.
As a leader in lifesciences, diagnostics and applied chemical markets, it is looking to grow its cancer diagnostics pipeline. Both of Biotheranostics’ diagnostics are PCR-based geneexpression tests. Agilent is a major provider of instruments, consumables, applications and services to laboratories worldwide.
Despite containing the same set of genes, cells are able to differentiate due to the regulatory role of microRNAs, which control geneexpression in a precise manner. Ambros and Ruvkun’s work demonstrated that small RNAs could repress geneexpression after mRNA was made, pointing to a previously unknown layer of genetic control.
The company’s ResolveOME multiomic workflow provides a comprehensive multiomic analysis of breast cancer through the use of exome hybrid capture alongside a single-cell workflow for single-cell resolution of single nucleotide variants (SNVs), copy number alterations and geneexpression signatures, coupled with a targeted protein panel.
.” In the new study, Ghosh and colleagues replaced the first and last steps in preclinical drug discovery with two novel approaches developed within the UC San Diego Institute for Network Medicine (iNetMed), which unites several research disciplines to develop new solutions to advance lifesciences and technology and enhance human health.
These modifications regulate geneexpression without altering the sequence or structure of DNA. Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the LifeSciences. We can do this for multiple genes at the same time without any DNA damage, and in a way that can be reversed.
Tapinarof treatment in a mouse model of psoriasis resulted in the downregulation of inflammatory cytokine expression in skin tissue, which involved IL17A , IL17F , IL19 , IL22 , IL23A and IL1B geneexpression. Clinical Trials of Vtama.
DNA vaccines designed using the platform consist of a combination of an advanced geneexpression plasmid (pDNA) with gene(s) of interest, and a probiotic bacterium to deliver the vaccine directly to the gut, where it binds to intestinal epithelial cells.
c-srRNA: A Temperature-Controllable Innovation Elixirgen Therapeutics’ c-srRNA platform offers a novel approach to controlling geneexpression through temperature sensitivity. The essence of the c-srRNA platform lies in its innovative use of temperature as a regulatory mechanism.
Her cryo-electron microscopy studies include analysis of nuclear peripheries and the machinery of geneexpression in bacteria. Innovative solutions such as those developed by Dr. Zitnik are essential for dealing with the massive amounts of data and their complexity in medicine and lifesciences. The Otto Bayer Award.
The pandemic propelled the lifescience and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the lifescience industry in 2020, it was a busy and positive year in many other areas.
The importance of identifying and combining signatures across multiple realms, from geneexpression to the proteome to the glycome, is important in the effective identification, classification and therapeutic targeting of disease in a more specified and personalized manner, and in contributing to our overall understanding of biological processes.
Daly’s histone research proved to be pioneering, being fundamental to our understanding of DNA packaging, geneexpression and epigenetics, among other areas in genetic research. She also established a scholarship fund at Queens College for African Americans in commemoration of her father in 1988.
Increasing KDM6A expression in male mice led them to be more resilient to the effects of amyloid beta plaques. The scientists also looked at public databases of geneexpression studies through which they discovered a particularly active variant of KDM6A that is present in about 13 percent of women and seven percent of men around the world.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content